ARCA biopharma
ARCA biopharma
ABIO
NASDAQ
11.40
USD
3.07%
About
Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The Company is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. It is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases.
The Company’s lead programs include ORKA-001 and ORKA-002, which are designed to block cytokines in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 is a potentially monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19).
ORKA-002 is a potentially monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions. ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 510.1K |
| Three Month Average Volume | 3.2M |
| High Low | |
| Fifty-Two Week High | 2.75 USD |
| Fifty-Two Week Low | 0.839 USD |
| Fifty-Two Week High Date | 29 Aug 2024 |
| Fifty-Two Week Low Date | 19 Jan 2024 |
| Price and Volume | |
| Current Price | 2.4 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 35.82% |
| Thirteen Week Relative Price Change | 12.69% |
| Twenty-Six Week Relative Price Change | 143.02% |
| Fifty-Two Week Relative Price Change | 73.72% |
| Year-to-Date Relative Price Change | 121.67% |
| Price Change | |
| One Day Price Change | -4.00% |
| Thirteen Week Price Change | 20.61% |
| Twenty-Six Week Price Change | 167.21% |
| Five Day Price Change | 7.27% |
| Fifty-Two Week Price Change | 117.68% |
| Year-to-Date Price Change | 162.50% |
| Month-to-Date Price Change | 48.75% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.5529 USD |
| Book Value Per Share (Most Recent Quarter) | 2.24531 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.5529 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 2.24531 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.63044 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.37036 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.49741 USD |
| Normalized (Last Fiscal Year) | -0.37036 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.37036 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.49741 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.37036 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.49741 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.58125 USD |
| Cash Per Share (Most Recent Quarter) | 2.29425 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.36931 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.49693 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.47619 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -20.01% |
| Tangible Book Value (5 Year) | 43.75% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -79.73% |
| EPS Change (Trailing Twelve Months) | -13.18% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -33,283,000 |
| Net Debt (Last Fiscal Year) | -37,431,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 59 |
| Current Ratio (Most Recent Quarter) | 27 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -5,014,000 |
| Free Cash Flow (Trailing Twelve Months) | -6,887,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -13.19% |
| Return on Assets (Trailing Twelve Months) | -19.22% |
| Return on Assets (5 Year) | -27.78% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -13.57% |
| Return on Equity (Trailing Twelve Months) | -20.05% |
| Return on Equity (5 Year) | -29.58% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -13.49% |
| Return on Investment (Trailing Twelve Months) | -19.99% |
| Return on Investment (5 Year) | -29.38% |